Immunome Inc.
IMNM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001472012
In the last 90 days, Immunome Inc. insiders filed 0 open-market purchases and 7 sales; 202 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Immunome Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 28 | 30 | +2 |
| Shares | 2.10M | 1.86M | −240.5K (−11.4%) |
| Value | $4.85M | $9.34M | +$4.50M (+92.8%) |
New holders (4)
Institutions that held Immunome Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Millennium Management LLC | 149,650 | $747.0K | 0.00% |
| HighTower Advisors, LLC | 16,818 | $83.0K | 0.00% |
| Dimensional Fund Advisors LP | 15,433 | $77.0K | 0.00% |
| Citadel Advisors LLC | 2,940 | $14.7K | 0.00% |
Sold out (2)
Institutions that held Immunome Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Advisor Group Holdings, Inc. | 1,229 | $3.00K |
| Bank of America Corp | 11 | $24 |